Wagener O E, Lieske J C, Toback F G
Department of Medicine, University of Chicago, IL 60637, USA.
New Horiz. 1995 Nov;3(4):634-49.
Acute renal failure (ARF) commonly occurs in critically ill patients. Despite improved dialysis techniques and recent advances in intensive care medicine, mortality from this condition remains unacceptably high. Increased understanding of the factors that mediate cellular injury, such as adenosine triphosphate depletion, intracellular calcium accumulation, and generation of reactive oxygenation species, as well as those that mediate recovery, such as locally produced and systemically released growth factors, provide fresh insights that can be used to develop new strategies to limit renal damage after acute insults and speed the repair process. Exogenous administration of growth factors, adenine nucleotides, and thyroxine, each of which can facilitate recovery of experimental ARF, in addition to factors yet to be identified, is a potentially exciting new therapeutic strategy to improve survival of patients with this condition.
急性肾衰竭(ARF)常见于危重病患者。尽管透析技术有所改进,重症监护医学也有了新进展,但这种疾病的死亡率仍然高得令人难以接受。对介导细胞损伤的因素(如三磷酸腺苷耗竭、细胞内钙蓄积和活性氧生成)以及介导恢复的因素(如局部产生和全身释放的生长因子)的认识不断增加,为开发新策略提供了新见解,这些新策略可用于限制急性损伤后的肾损伤并加速修复过程。除了尚未确定的因素外,外源性给予生长因子、腺嘌呤核苷酸和甲状腺素,每一种都可以促进实验性ARF的恢复,这是一种潜在的令人兴奋的新治疗策略,有望提高这种疾病患者的生存率。